CVnCoV COVID-19 vaccine safely elicits immune response in Phase I testing
The interim Phase I data suggests CVnCoV can safely induce…
The interim Phase I data suggests CVnCoV can safely induce a neutralising antibody response similar to that of convalescent COVID-19 patients with two 12μg vaccine doses.